Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. 2003

Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
Department of Pharmacology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.

To address the functional alterations of monoaminergic neuronal systems in mice after single and repeated administration of methamphetamine, we examined the tissue contents of monoamines and their metabolites in addition to locomotor activity estimated by horizontal locomotion and rearing measurements. In male ICR mice, the repeated treatment regimen (intraperitoneal administration of 1.0 mg/kg methamphetamine once per day for five consecutive days) induced hyperlocomotion with a plateau level on test day 4. The initial behavioral response (within 5 min after injection) to the drug appeared to include context-dependent sensitization. Mice after the initial repeated treatment regimen showed behavioral sensitization to the same dose of methamphetamine 5 days after the final injection (test day 11). On test day 11, the first 150 min, but not the nocturnal behavior (during the dark hours), were significantly enhanced after the drug challenge. A marked reduction of the content of L-dihydroxyphenylalanine and the ratio of 3,4-dihydroxyphenylacetic acid to dopamine was observed in the striatum+accumbens of mice after single and repeated administration of methamphetamine. As for serotonin metabolism, the ratio of 5-hydroxyindolacetic acid to serotonin significantly increased in mice after single administration of methamphetamine, although it decreased in mice after repeated administration of methamphetamine. Norepinephrine metabolism (the ratio of 3-methoxy-4-hydroxyphenylglycol to norepinephrine) was not affected in the striatum+accumbens or thalamus+hypothalamus of the mice after repeated or single methamphetamine treatment. These results suggest that dopaminergic and serotonergic neuronal activities were altered during the development of behavioral sensitization. The ratio of 3-methoxytyramine to dopamine was not affected, suggesting that the methamphetamine treatment selectively inhibited the monoamine oxidase pathway for dopamine inactivation.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008297 Male Males
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D015306 Biogenic Monoamines Biogenic amines having only one amine moiety. Included in this group are all natural monoamines formed by the enzymatic decarboxylation of natural amino acids. Monoamines, Biogenic

Related Publications

Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
February 2014, Neuroscience letters,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
January 2012, PloS one,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
September 2007, Synapse (New York, N.Y.),
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
September 2007, Psychopharmacology,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
April 2002, European journal of pharmacology,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
December 1991, The Journal of pharmacy and pharmacology,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
June 1986, Japanese journal of pharmacology,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
September 2005, Brain research bulletin,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
February 1997, Progress in neuro-psychopharmacology & biological psychiatry,
Nobue Kitanaka, and Junichi Kitanaka, and Motohiko Takemura
June 2006, Neuropharmacology,
Copied contents to your clipboard!